𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of once-daily inhaled ciclesonide in adults with mild to moderate asthma: A double-blind, placebo-controlled study

✍ Scribed by Mitsuru ADACHI; Kyosuke ISHIHARA; Hiroshi INOUE; Koichiro KUDO; Kiyoshi TAKAHASHI; Yutaka MORITA; Ken-Ichi MASUDA; Yoshinori TAKADA; Ryuichi KATO; Terumasa MIYAMOTO

Book ID
108964680
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
159 KB
Volume
12
Category
Article
ISSN
1323-7799

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Safety and tolerability of once-daily ve
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
✍ Roy W. Jones; Antony Bayer; Fraser Inglis; Andrew Barker; Ravinder Phul πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views

## Abstract ## Objective To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD). ## Method This 12‐week, randomised, double‐blind study, investigated three dosing schedules of memantine: OD1 (20 mg once

A multicentre, randomized, double-blind,
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 139 KB πŸ‘ 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre